Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 678Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
Year : 2018  |  Volume : 9  |  Issue : 2  |  Page : 107-108

Antidiabetic medication and quality of life: A comment on Chaturvedi et al. (2018)

Department of Community Medicine, Maulana Azad Medical College, New Delhi, India

Date of Web Publication24-Apr-2018

Correspondence Address:
Dr. Saurav Basu
Department of Community Medicine, Maulana Azad Medical College, New Delhi,
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/picr.PICR_6_18

Rights and Permissions

How to cite this article:
Basu S. Antidiabetic medication and quality of life: A comment on Chaturvedi et al. (2018). Perspect Clin Res 2018;9:107-8

How to cite this URL:
Basu S. Antidiabetic medication and quality of life: A comment on Chaturvedi et al. (2018). Perspect Clin Res [serial online] 2018 [cited 2022 Jan 17];9:107-8. Available from: https://www.picronline.org/text.asp?2018/9/2/107/231101

Dear Editor,

I read the article by Chaturvedi et al. (2018) with considerable interest.[1] Measures for improving the quality of life (QOL) should be treated as an essential part of diabetic care. The findings of the authors show that improving QOL correlates with improvement in metabolic outcomes such as glycemic control. However, I have two concerns regarding the methodology and conclusion advanced by the author which need clarification.

The authors wanted to answer the research question that whether antidiabetic drug treatment improves the QOL and other biochemical parameters in diabetes mellitus (DM) patients. However, the mean duration of diabetes in the patients was over 10 years, so most patients were likely to be on treatment before enrollment in the Chaturvedi (2018) study. In this regard, for the study to have answered the desired research question, it should have preferably included only newly diagnosed DM patients who were previously not on standard antidiabetic treatment consisting of either oral hypoglycemic agents (OHAs) or insulin. This is because QOL and metabolic outcomes in DM patients are not constant but are likely to show variation with time depending on patient factors such as level of stress, extent of medical adherence, change in drug therapy, or onset of any diabetes-related complications.[2] Among the previously diagnosed patients on antidiabetic treatment, therapeutic outcomes such as glycemic control are likely to improve on increasing adherence to medication, self-care practices, reducing stress, and intensification of drug therapy using newer OHAs or insulin.[3] The Chaturvedi (2018) study should report the change in the determinants of the above study outcomes during the 6-month period of observation.

The authors concluded that using fewer medicines offers better treatment satisfaction and QOL in the patient. Nevertheless, the authors finding could be due to confounding since patients with recent onset of DM need fewer medicines to manage their diabetes and are less likely to suffer diabetes-related complications compared to DM patients with long duration of diabetes.[4] Moreover, the failure to sufficiently intensify the antidiabetic treatment in patients with poor glycemic control poses the risk of therapeutic inertia and likelihood of adverse health outcomes.[5]

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Chaturvedi R, Desai C, Patel P, Shah A, Dikshit RK. An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus. Perspect Clin Res 2018;9:15-22.  Back to cited text no. 1
[PUBMED]  [Full text]  
Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes 2017;8:120-9.  Back to cited text no. 2
Basu S, Khobragade M, Kumar A, Raut DK. Medical adherence and its predictors in diabetes mellitus patients attending government hospitals in the Indian capital, Delhi, 2013: A cross sectional study. Int J Diabetes Dev Ctries 2015;35 Suppl 2:95.  Back to cited text no. 3
Hayashino Y, Izumi K, Okamura S, Nishimura R, Origasa H, Tajima N, et al. Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: The Japan diabetes complication and its prevention prospective study 3 (JDCP study 3). J Diabetes Investig 2017;8:243-9.  Back to cited text no. 4
Bailey CJ. Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. Int J Clin Pract 2016;70:988-95.  Back to cited text no. 5


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded167    
    Comments [Add]    

Recommend this journal